Adair Jason sold $5.1M of LQDA

Liquidia Corporation (LQDA) shares fell 57% after a patent litigation ruling. The decision may limit YUTREPIA's market competition and benefit Tyvaso, impacting Liquidia's commercial prospects. Analysts cite unresolved patent disputes as a key risk.

Liquidia (LQDA) shares fell 57% while United Therapeutics (UTHR) rose 13% after a judge ruled LQDA's Yutrepia infringes two UTHR patents. The court ordered a final judgment within a week. LQDA plans to appeal and may seek FDA label changes. UTHR seeks an injunction. Retail sentiment shifted bullish for UTHR and mixed for LQDA.

Liquidia Corp (LQDA) fell 48% to $36.87 after a court ruled it infringed United Therapeutics' (UTHR) patent, impacting its YUTREPIA drug. Liquidia plans to remove a key indication and may face further restrictions. Options activity surged, with a mix of speculative and hedging trades. UTHR shares rose on the ruling.

Liquidia Corporation's stock fell 48.3% to $36.55 after a court ruled it infringed two claims of United Therapeutics' patent, impacting its YUTREPIA drug. The company plans to remove a key indication and may face further restrictions. United Therapeutics' stock rose. The broader market gained slightly.

Liquidia (LQDA) was found to have infringed on United Therapeutics' (UTHR) patents for its drug Yutrepia, which treats high blood pressure in the lungs. The ruling caused the stocks to diverge, as UTHR's Tyvaso is a direct competitor to Yutrepia. The companies have been in a legal battle for years.

Liquidia Corp shares fell after a U.S. court ruled it infringed two patents held by United Therapeutics Corp, which saw shares rise over 13%. The ruling concerns pulmonary hypertension treatment. Liquidia plans to appeal and may remove the indication from its drug's label. The court will decide on remedies within a week.